{"id":41169,"date":"2025-09-11T16:25:57","date_gmt":"2025-09-11T08:25:57","guid":{"rendered":"https:\/\/flcube.com\/?p=41169"},"modified":"2025-09-11T16:25:58","modified_gmt":"2025-09-11T08:25:58","slug":"china-to-add-hpv-vaccine-to-national-immunization-program-pledges-free-shots-for-eligible-girls","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41169","title":{"rendered":"China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls"},"content":{"rendered":"\n

At a State Council Information Office press conference, Deputy Director of the National Health Commission (NHC) and Director of the National Disease Control and Prevention Administration (NDCPA), Shen\u202fHongbing<\/strong>, announced that the Human Papillomavirus (HPV) vaccine will be incorporated into China\u2019s National Immunization Program (NIP) within the year. The move will provide free vaccinations<\/strong> to eligible girls nationwide, expanding on pilot efforts already underway in Guangdong, Hainan, and Shandong.<\/p>\n\n\n\n

What the Announcement Means<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Program Inclusion<\/strong><\/td>HPV vaccine added to the 2025 NIP schedule<\/td><\/tr>
Target Group<\/strong><\/td>Eligible girls (typically 9\u201114\u202fyears; exact age brackets to be finalized)<\/td><\/tr>
Funding<\/strong><\/td>Fully government\u2011funded; no out\u2011of\u2011pocket cost for recipients<\/td><\/tr>
Implementation Roadmap<\/strong><\/td>Roll\u2011out to begin in 2026, with phased expansion to all provinces<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Current Vaccine Landscape in China<\/h3>\n\n\n\n

China has six licensed HPV vaccines, spanning bivalent, quadrivalent, and nonavalent formulations:<\/p>\n\n\n\n

Vaccine<\/th>Manufacturer<\/th>Type<\/th>Current Market Status<\/th><\/tr><\/thead>
Cecolin<\/strong><\/td>Wantai Bio<\/td>Bivalent<\/td>Widely procured in Shandong at <\u202f100\u202fRMB\/dose<\/td><\/tr>
Wozehui<\/strong><\/td>Walvax<\/td>Bivalent<\/td>Available, used in pilot programs<\/td><\/tr>
Cervarix<\/strong><\/td>GSK<\/td>Bivalent<\/td>Licensed, used in select regions<\/td><\/tr>
Gardasil\u202f4<\/strong><\/td>MSD<\/td>Quadrivalent<\/td>Licensed, limited use<\/td><\/tr>
Gardasil\u202f9<\/strong><\/td>MSD<\/td>Nonavalent<\/td>Licensed, used in pilot programs<\/td><\/tr>
Cecolin\u202f9<\/strong><\/td>Wantai Bio<\/td>Nonavalent<\/td>Newly approved, entering procurement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Domestic bivalent vaccines have already secured procurement bids in provinces such as Shandong, with unit prices falling below 100\u202fRMB, making them highly cost\u2011effective for mass immunization.<\/p>\n\n\n\n

Policy Context & Regional Pilots<\/h3>\n\n\n\n